Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBIT (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of EBIT data on record, last reported at -$24.0 million in Q3 2025.

  • For Q3 2025, EBIT fell 56.52% year-over-year to -$24.0 million; the TTM value through Sep 2025 reached -$83.2 million, down 36.97%, while the annual FY2024 figure was -$64.2 million, 36.23% down from the prior year.
  • EBIT reached -$24.0 million in Q3 2025 per ABEO's latest filing, down from -$22.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$8.0 million in Q2 2022 and bottomed at -$46.7 million in Q4 2021.
  • Average EBIT over 5 years is -$16.8 million, with a median of -$14.6 million recorded in 2021.
  • Peak YoY movement for EBIT: tumbled 138.03% in 2021, then skyrocketed 72.27% in 2022.
  • A 5-year view of EBIT shows it stood at -$46.7 million in 2021, then surged by 72.27% to -$12.9 million in 2022, then decreased by 2.11% to -$13.2 million in 2023, then decreased by 26.22% to -$16.7 million in 2024, then tumbled by 44.06% to -$24.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$24.0 million in Q3 2025, -$22.8 million in Q2 2025, and -$19.7 million in Q1 2025.